Welcome to the UPF Digital Repository

Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

Show simple item record

dc.contributor.author García-Foncillas, Jesús
dc.contributor.author Tabernero Cartula, Josep
dc.contributor.author Élez, Elena
dc.contributor.author Aranda, Enrique
dc.contributor.author Benavides, Manuel
dc.contributor.author Camps, Carlos
dc.contributor.author Jantus-Lewintre, Eloisa
dc.contributor.author López, Rafael
dc.contributor.author Muinelo-Romay, Laura
dc.contributor.author Montagut Viladot, Clara
dc.contributor.author Antón, Antonio
dc.contributor.author López, Guillermo
dc.contributor.author Díaz-Rubio, Eduardo
dc.contributor.author Rojo, Federico
dc.contributor.author Vivancos Prellezo, Ana
dc.date.accessioned 2019-03-21T08:24:14Z
dc.date.issued 2018
dc.identifier.citation García-Foncillas J, Tabernero J, Élez E, Aranda E, Benavides M, Camps C. et al. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br J Cancer. 2018 Dec;119(12):1464-1470. DOI: 10.1038/s41416-018-0293-5
dc.identifier.issn 0007-0920
dc.identifier.uri http://hdl.handle.net/10230/36880
dc.description.abstract BACKGROUND: Liquid biopsy offers a minimally invasive alternative to tissue-based evaluation of mutational status in cancer. The goal of the present study was to evaluate the aggregate performance of OncoBEAM RAS mutation analysis in plasma of colorectal cancer (CRC) patients at 10 hospital laboratories in Spain where this technology is routinely implemented. METHODS: Circulating cell-free DNA from plasma was examined for RAS mutations using the OncoBEAM platform at each hospital laboratory. Results were then compared to those obtained from DNA extracted from tumour tissue from the same patient. RESULTS: The overall percentage agreement between plasma-based and tissue-based RAS mutation testing of the 236 participants was 89% (210/236; kappa, 0.770 (95% CI: 0.689-0.852)). Re-analysis of tissue from all discordant cases by BEAMing revealed two false negative and five false positive tumour tissue RAS results, with a final concordance of 92%. Plasma false negative results were found more frequently in patients with exclusive lung metastatic disease. CONCLUSIONS: In this first prospective real-world RAS mutation performance comparison study, a high overall agreement was observed between results obtained from plasma and tissue samples. Overall, these findings indicate that the plasma-based BEAMing assay is a viable solution for rapid delivery of RAS mutation status to determine mCRC patient eligibility for anti-EGFR therapy.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Nature Research
dc.rights © Springer Nature Publishing AG García-Foncillas J, Tabernero J, Élez E, Aranda E, Benavides M, Camps C. et al. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer. Br J Cancer. 2018 Dec;119(12):1464-1470. http://dx.doi.org/10.1038/s41416-018-0293-5
dc.subject.other Còlon -- Càncer -- Aspectes genètics
dc.title Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1038/s41416-018-0293-5
dc.rights.accessRights info:eu-repo/semantics/embargoedAccess
dc.type.version info:eu-repo/semantics/acceptedVersion
dc.embargo.liftdate 2019-06-30
dc.date.embargoEnd info:eu-repo/date/embargoEnd/2019-06-30

Blocked

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics

Compliant to Partaking